{"id":8719,"date":"2026-01-20T13:18:15","date_gmt":"2026-01-20T12:18:15","guid":{"rendered":"https:\/\/fgk-group.com\/?post_type=knowledge-hub-mag&p=8719"},"modified":"2026-01-20T15:01:32","modified_gmt":"2026-01-20T14:01:32","slug":"how-germany-is-boosting-clinical-research-reimbursement-benefits","status":"publish","type":"knowledge-hub-mag","link":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/","title":{"rendered":"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Germany\u2019s 5% rule: trials with enough local patients are exempt from additional reimbursement price cuts \u2013 making the country more attractive for pharma. Picture by FGK generated with AI<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t

HOW GERMANY IS BOOSTING CLINICAL RESEARCH: PART 4 - REIMBURSEMENT BENEFITS<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Author: Ariane Helfrich, PhD<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

Bringing a new drug to patients involves high costs for pharmaceutical companies. In 2024, the pharmaceutical industry spend around \u20ac55 billion for R&D in Europe1<\/sup>. During the drug approval process, approximately 90% of drug candidates that enter clinical trials fail to receive marketing approval due to lack of clinical efficacy or safety concerns2<\/sup>. The remaining 10% must be used to cover the companies‘ expenses.<\/p>

Since 2011, the German Act on the Reform of the Pharmaceutical Market (AMNOG) has been the central instrument for this process and has fundamentally changed the landscape of drug pricing in Germany. The German approach guarantees patients immediate access to innovations, which distinguishes it from many other European systems. In Germany, the average time between approval and availability of drugs, including the reimbursement status of the new drug, was 128 days (as of January 5, 2025)3<\/sup>. Initially, market access is granted at a price set by the pharmaceutical manufacture. However, after six months at the latest, the negotiated reimbursement amount comes into effect, which is intended to reflect the actual value of the innovation. The AMNOG process follows the principle that the price of a drug must reflect its proven benefit. Drugs with significant added value over currently available therapies justify higher prices.<\/p>

The AMNOG system is continuously being developed further. Since its introduction, legislators have made regular adjustments to maintain the balance between innovation and affordability. One of the government’s goals is to create additional treatment options for patients by encouraging pharmaceutical companies to conduct clinical studies in Germany. Various measures are taken to make Germany an attractive place for pharmaceutical companies to conduct clinical trials. The government recognizes the pharmaceutical industry as a key industry in Germany. Therefore, the German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants<\/a><\/strong> in Germany to be exempt from additional discounts and price caps that were decided in 20224<\/sup>. This exemption from the benefit assessment under AMNOG could be attractive to pharmaceutical companies, as the prices of new drugs would then no longer be measured so strictly against their added benefit compared to existing therapies. In this way, the government is sending an important signal to patients and research-active pharmaceutical manufacturers.<\/p>

Thanks to various measures, Germany is once again establishing itself as the preferred destination for clinical trials. With regulatory clarity, speed, and scientific excellence, Germany is your ideal partner for clinical development.<\/p>

As your partner for clinical trials, FGK can bring your study into life \u2013 efficiently and successfully.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t

References:<\/strong><\/span><\/p>

1 EFPIA. (26. Juni, 2025). Ausgaben f\u00fcr Forschung und Entwicklung der europ\u00e4ischen Pharmaindustrie im Zeitraum von 1990 bis 2024 (in Millionen Euro) [Graph]. In\u00a0Statista<\/em>. Zugriff am 29. Juli 2025, von https:\/\/de.statista.com\/statistik\/daten\/studie\/70870\/umfrage\/pharmaindustrie-ausgaben-fuer-forschung-und-entwicklung\/<\/a><\/strong><\/p>

2 Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022 Jul;12(7):3049-3062. doi: 10.1016\/j.apsb.2022.02.002. Epub 2022 Feb 11. PMID: 35865092; PMCID: PMC9293739.<\/p>

3 IQVIA, & EFPIA. (May 26, 2025). Average time between marketing authorization and patient access for new medicines in Europe as of 2025, by country (in days) [Graph]. In\u00a0Statista<\/em>. Retrieved July 28, 2025, from https:\/\/www.statista.com\/statistics\/1011197\/europe-time-between-medicine-authorization-and-access\/<\/a><\/strong><\/p>

4 https:\/\/www.vfa.de\/de\/presse\/pressemitteilungen\/pm-022-2024-ampelkoalition-staerkt-schluesselindustrie-pharma.html<\/a><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

The German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants in Germany to be exempt from additional discounts and price caps that were decided in 2022.<\/p>\n","protected":false},"featured_media":8718,"template":"","class_list":["post-8719","knowledge-hub-mag","type-knowledge-hub-mag","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nHow Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits - FGK Group<\/title>\n<meta name=\"description\" content=\"The German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants in Germany to be exempt from additional discounts and price caps that were decided in 2022.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits - FGK Group\" \/>\n<meta property=\"og:description\" content=\"The German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants in Germany to be exempt from additional discounts and price caps that were decided in 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/\" \/>\n<meta property=\"og:site_name\" content=\"FGK Group\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T14:01:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fgk-group.com\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/\",\"url\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/\",\"name\":\"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits - FGK Group\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fgk-group.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png\",\"datePublished\":\"2026-01-20T12:18:15+00:00\",\"dateModified\":\"2026-01-20T14:01:32+00:00\",\"description\":\"The German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants in Germany to be exempt from additional discounts and price caps that were decided in 2022.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fgk-group.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png\",\"contentUrl\":\"https:\\\/\\\/fgk-group.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png\",\"width\":1024,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/how-germany-is-boosting-clinical-research-reimbursement-benefits\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Magazine\",\"item\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/knowledge-hub\\\/magazin\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/\",\"name\":\"FGK Group\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fgk-group.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits - FGK Group","description":"The German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants in Germany to be exempt from additional discounts and price caps that were decided in 2022.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/","og_locale":"de_DE","og_type":"article","og_title":"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits - FGK Group","og_description":"The German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants in Germany to be exempt from additional discounts and price caps that were decided in 2022.","og_url":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/","og_site_name":"FGK Group","article_modified_time":"2026-01-20T14:01:32+00:00","og_image":[{"width":1024,"height":1024,"url":"https:\/\/fgk-group.com\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/","url":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/","name":"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits - FGK Group","isPartOf":{"@id":"https:\/\/fgk-group.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/#primaryimage"},"image":{"@id":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/#primaryimage"},"thumbnailUrl":"https:\/\/fgk-group.com\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png","datePublished":"2026-01-20T12:18:15+00:00","dateModified":"2026-01-20T14:01:32+00:00","description":"The German Medical Research Act allows pharmaceutical manufactures that have recruited at least 5% of participants in Germany to be exempt from additional discounts and price caps that were decided in 2022.","breadcrumb":{"@id":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/#primaryimage","url":"https:\/\/fgk-group.com\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png","contentUrl":"https:\/\/fgk-group.com\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-Sep-6-2025-08_43_13-AM.png","width":1024,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/how-germany-is-boosting-clinical-research-reimbursement-benefits\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fgk-group.com\/de\/"},{"@type":"ListItem","position":2,"name":"Magazine","item":"https:\/\/fgk-group.com\/de\/knowledge-hub\/magazin\/"},{"@type":"ListItem","position":3,"name":"How Germany is boosting Clinical Research: Part 4 \u2013 Reimbursement Benefits"}]},{"@type":"WebSite","@id":"https:\/\/fgk-group.com\/de\/#website","url":"https:\/\/fgk-group.com\/de\/","name":"FGK Group","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fgk-group.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"}]}},"_links":{"self":[{"href":"https:\/\/fgk-group.com\/de\/wp-json\/wp\/v2\/knowledge-hub-mag\/8719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fgk-group.com\/de\/wp-json\/wp\/v2\/knowledge-hub-mag"}],"about":[{"href":"https:\/\/fgk-group.com\/de\/wp-json\/wp\/v2\/types\/knowledge-hub-mag"}],"version-history":[{"count":2,"href":"https:\/\/fgk-group.com\/de\/wp-json\/wp\/v2\/knowledge-hub-mag\/8719\/revisions"}],"predecessor-version":[{"id":8725,"href":"https:\/\/fgk-group.com\/de\/wp-json\/wp\/v2\/knowledge-hub-mag\/8719\/revisions\/8725"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fgk-group.com\/de\/wp-json\/wp\/v2\/media\/8718"}],"wp:attachment":[{"href":"https:\/\/fgk-group.com\/de\/wp-json\/wp\/v2\/media?parent=8719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}